Drug intelligence / Profile preview

GS19

Development stage: Preclinical
Lead developer: Gensun Biopharma
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

**GS19** is a PD-L1/TGF-β dual-targeting monoclonal antibody developed by Gensun Biopharma, featuring genetic engineering modifications to reduce degradation or fragmentation during CHO cell expression, facilitating commercial production and positioning it as a potential best-in-class oncology therapeutic. It exhibits high inhibitory activity against both PD-L1, a key immune checkpoint, and TGF-βR2, which promotes tumor immunosuppression and fibrosis. Kintor Pharmaceutical holds exclusive rights for its clinical development and commercialization in Greater China, with plans to accelerate preclinical studies toward IND filing and explore combinations, such as with an ALK-1 antibody, for advanced liver cancer.[1][4]

Targets

CD274 (Programmed cell death protein 1 ligand 1)TGFBR2 (TGF-β receptor type 2)

Beyond the preview

Go deeper on GS19.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GS19.

Explore the full profile